- Home
- NLSP vs LYRA Comparison
NLSP vs LYRA Comparison
Compare NLSP & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- LYRA
- Stock Information
- Founded
- NLSP 2015
- LYRA 2005
- Country
- NLSP Switzerland
- LYRA United States
- Employees
- NLSP N/A
- LYRA N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- NLSP Health Care
- LYRA Health Care
- Exchange
- NLSP Nasdaq
- LYRA Nasdaq
- Market Cap
- NLSP 12.4M
- LYRA 11.3M
- IPO Year
- NLSP 2021
- LYRA 2020
- Fundamental
- Price
- NLSP $2.17
- LYRA $6.23
- Analyst Decision
- NLSP
- LYRA Hold
- Analyst Count
- NLSP 0
- LYRA 1
- Target Price
- NLSP N/A
- LYRA $16.00
- AVG Volume (30 Days)
- NLSP 193.3K
- LYRA 15.1K
- Earning Date
- NLSP 10-17-2025
- LYRA 11-11-2025
- Dividend Yield
- NLSP N/A
- LYRA N/A
- EPS Growth
- NLSP N/A
- LYRA N/A
- EPS
- NLSP N/A
- LYRA N/A
- Revenue
- NLSP N/A
- LYRA $770,000.00
- Revenue This Year
- NLSP N/A
- LYRA N/A
- Revenue Next Year
- NLSP N/A
- LYRA $123.46
- P/E Ratio
- NLSP N/A
- LYRA N/A
- Revenue Growth
- NLSP N/A
- LYRA N/A
- 52 Week Low
- NLSP $1.30
- LYRA $3.81
- 52 Week High
- NLSP $6.97
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- NLSP 49.81
- LYRA 34.49
- Support Level
- NLSP $1.88
- LYRA $6.15
- Resistance Level
- NLSP $2.02
- LYRA $6.72
- Average True Range (ATR)
- NLSP 0.13
- LYRA 0.38
- MACD
- NLSP -0.01
- LYRA -0.04
- Stochastic Oscillator
- NLSP 55.94
- LYRA 13.35
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.